60 Degrees Pharmaceuticals (SXTP) Equity Average (2022 - 2025)
Historic Equity Average for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $3.4 million.
- 60 Degrees Pharmaceuticals' Equity Average fell 2405.57% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 2405.57%. This contributed to the annual value of $4.4 million for FY2024, which is 14564.99% up from last year.
- 60 Degrees Pharmaceuticals' Equity Average amounted to $3.4 million in Q3 2025, which was down 2405.57% from $3.2 million recorded in Q2 2025.
- 60 Degrees Pharmaceuticals' 5-year Equity Average high stood at $6.0 million for Q1 2024, and its period low was -$23.3 million during Q4 2022.
- Over the past 4 years, 60 Degrees Pharmaceuticals' median Equity Average value was $3.4 million (recorded in 2025), while the average stood at -$4.9 million.
- In the last 5 years, 60 Degrees Pharmaceuticals' Equity Average surged by 14903.22% in 2024 and then tumbled by 3679.05% in 2025.
- 60 Degrees Pharmaceuticals' Equity Average (Quarter) stood at -$23.3 million in 2022, then skyrocketed by 124.26% to $5.7 million in 2023, then fell by 11.63% to $5.0 million in 2024, then plummeted by 32.23% to $3.4 million in 2025.
- Its Equity Average stands at $3.4 million for Q3 2025, versus $3.2 million for Q2 2025 and $4.0 million for Q1 2025.